HIV-1 Viral protein-r (Vpr) protects against lethal superantigen challenge while maintaining homeostatic T cell levels in vivo.

[1]  D. Weiner,et al.  HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. , 2004, International immunology.

[2]  D. Weiner,et al.  HIV-1 Vpr and anti-inflammatory activity. , 2004, DNA and cell biology.

[3]  J. J. Kim.  Using viral genomics to develop viral gene products as a novel class of drugs to treat human ailments , 2001, Biotechnology Letters.

[4]  E. Connick,et al.  CD8+ T cells that express CD4 on their surface (CD4dimCD8bright T cells) recognize an antigen-specific target, are detected in vivo, and can be productively infected by T-tropic HIV. , 2003, Blood.

[5]  S. Bavari,et al.  Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. , 2003, Clinical immunology.

[6]  S. Volpi,et al.  HIV-1 Protein Vpr Suppresses IL-12 Production from Human Monocytes by Enhancing Glucocorticoid Action: Potential Implications of Vpr Coactivator Activity for the Innate and Cellular Immunity Deficits Observed in HIV-1 Infection , 2002, The Journal of Immunology.

[7]  W. Greene,et al.  HIV-1 Vpr displays natural protein-transducing properties: implications for viral pathogenesis. , 2002, Virology.

[8]  D. Green,et al.  HIV-1 Vpr Induces Apoptosis through Caspase 9 in T Cells and Peripheral Blood Mononuclear Cells* , 2002, The Journal of Biological Chemistry.

[9]  J. Kim,et al.  Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques , 2002, Journal of medical primatology.

[10]  A. Weiss,et al.  It's all Rel-ative: NF-kappaB and CD28 costimulation of T-cell activation. , 2002, Trends in immunology.

[11]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[12]  N. Tanaka,et al.  Differential Cytokine Response in Host Defence Mechanisms Triggered by Gram-Negative and Gram-Positive Bacteria, and the Roles of Gabexate Mesilate, a Synthetic Protease Inhibitor , 2002, The Journal of international medical research.

[13]  J. Kim,et al.  HIV-1 viral protein R compromises cellular immune function in vivo. , 2002, International immunology.

[14]  C. Jacob,et al.  In vivo staphylococcal superantigen-driven polyclonal Ig responses in mice: dependence upon CD4(+) cells and human MHC class II. , 2001, International immunology.

[15]  J. Zack,et al.  Upregulation of CD4 on CD8+ T cells: CD4dimCD8bright T cells constitute an activated phenotype of CD8+ T cells , 2001, Immunology.

[16]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[17]  J. McCune,et al.  The dynamics of CD4+ T-cell depletion in HIV disease , 2001, Nature.

[18]  J. McCormick,et al.  Toxic shock syndrome and bacterial superantigens: an update. , 2001, Annual review of microbiology.

[19]  B. Spratt,et al.  Recombination and the population structures of bacterial pathogens. , 2001, Annual review of microbiology.

[20]  R. Pomerantz,et al.  Human Immunodeficiency Virus Type 1 Vpr Induces Apoptosis in Human Neuronal Cells , 2000, Journal of Virology.

[21]  D. Weiner,et al.  HIV‐1 Vpr regulates expression of β chemokines in human primary lymphocytes and macrophages , 2000, Journal of leukocyte biology.

[22]  R. Balk.  Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. , 2000, Critical care clinics.

[23]  R. Balk,et al.  SEVERE SEPSIS AND SEPTIC SHOCK , 2000 .

[24]  R. Kaempfer,et al.  Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation , 2000, Nature Medicine.

[25]  S. Berrih-Aknin,et al.  T cell deletion and unresponsiveness induced by intrathymic injection of staphylococcal enterotoxin B. , 2000, Transplant immunology.

[26]  C. Du,et al.  Induction of interleukin-12/p40 by superantigens in macrophages is mediated by activation of nuclear factor-kappaB. , 2000, Cellular immunology.

[27]  G. Kroemer,et al.  The HIV-1 Viral Protein R Induces Apoptosis via a Direct Effect on the Mitochondrial Permeability Transition Pore , 2000, The Journal of experimental medicine.

[28]  G. Chrousos,et al.  The HIV-1 Virion-associated Protein Vpr Is a Coactivator of the Human Glucocorticoid Receptor , 1999, Psychoneuroendocrinology.

[29]  M. Karin,et al.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.

[30]  I. Chen,et al.  Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Cohen,et al.  Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis. , 1999, Infectious disease clinics of North America.

[32]  A P Wheeler,et al.  Treating patients with severe sepsis. , 1999, The New England journal of medicine.

[33]  A. Satoskar,et al.  Targeted Disruption of Migration Inhibitory Factor Gene Reveals Its Critical Role in Sepsis , 1999, The Journal of experimental medicine.

[34]  N. Letvin.  Progress in the development of an HIV-1 vaccine. , 1998, Science.

[35]  É. Cohen,et al.  Human Immunodeficiency Virus Type 1 Vpr Is a Positive Regulator of  Viral Transcription and Infectivity in Primary Human Macrophages , 1998, The Journal of experimental medicine.

[36]  D. Green,et al.  HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor κB , 1997, Nature Medicine.

[37]  C. Natanson,et al.  Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. , 1997, Critical care medicine.

[38]  J. Cavaillon,et al.  Cytokines in Streptococcal Infections , 1997 .

[39]  M. Emerman.  HIV-1, Vpr and the cell cycle , 1996, Current Biology.

[40]  M. Emerman,et al.  Protein stability influences human immunodeficiency virus type 2 Vpr virion incorporation and cell cycle effect. , 1996, Virology.

[41]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[42]  D O Morgan,et al.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity , 1995, Journal of virology.

[43]  Joseph A. DiDonato,et al.  Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis , 1995, Science.

[44]  T. Tan,et al.  Effect of CD28 signal transduction on c-Rel in human peripheral blood T cells , 1994, Molecular and cellular biology.

[45]  D. Weiner,et al.  Induction of cell differentiation by human immunodeficiency virus 1 vpr , 1993, Cell.

[46]  J. Fraser,et al.  Enterotoxin residues determining T-cell receptor Vβ binding specificity , 1992, Nature.

[47]  W. Haseltine,et al.  Molecular biology of the human immunodeficiency virus type 1 , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  P. Marrack,et al.  Residues of the variable region of the T-cell-receptor β-chain that interact with S. aureus toxin superantigens , 1990, Nature.

[49]  J. Sodroski,et al.  Human immunodeficiency virus vpr product is a virion-associated regulatory protein , 1990, Journal of virology.

[50]  D. Baltimore,et al.  Activation in vitro of NF-κB" by phosphorylation of its inhibitor IκB" , 1990, Nature.